Phosphodiesterase 4 Inhibitors Augment Levels of Glucocorticoid Receptor in B Cell Chronic Lymphocytic Leukemia but Not in Normal Circulating Hematopoietic Cells

John A. Meyers,1,2 Josephine Taverna,3 Jorge Chaves,1 Anthony Makkinje,1 and Adam Lerner1,2

Abstract

Type 4 cyclic AMP (cAMP) phosphodiesterase (PDE4) inhibitors, a class of compounds in clinical development that activate cAMP-mediated signaling by inhibiting cAMP catabolism, offer a feasible means by which to potentiate glucocorticoid-mediated apoptosis in lymphoid malignancies such as B-cell chronic lymphocytic leukemia (B-CLL). In this study, we show that PDE4 inhibitors up-regulate glucocorticoid receptor (GRα) transcript levels in B-CLL cells but not T-CLL cells or Sezary cells or normal circulating T cells, B cells, monocytes, or neutrophils. Because GRα transcript half-life does not vary in CLL cells treated with the prototypic PDE4 inhibitor rolipram, the 4-fold increase in GRα mRNA levels observed within 4 h of rolipram treatment seems to result from an increase in GRα transcription. Rolipram treatment increases levels of transcripts derived from the 1A3 promoter to a greater extent than the 1B promoter. Treatment of B-CLL cells with two other PDE4 inhibitors currently in clinical development also augments GR transcript levels and glucocorticoid-mediated apoptosis. Washout studies show that simultaneous treatment with both drug classes irreversibly augments apoptosis over the same time frame that GR up-regulation occurs. Although treatment of B-CLL cells with glucocorticoids reduces basal GRα transcript levels in a dose-related manner, cotreatment with rolipram maintained GRα transcript levels above baseline. Our results suggest that as a result of their unusual sensitivity to PDE4 inhibitor–mediated up-regulation of GRα expression, treatment of B-CLL patients with combined PDE4 inhibitor/glucocorticoid therapy may be of therapeutic benefit in this disease.

Glucocorticoids are an important component of standard therapy for several lymphoid malignancies, including multiple myeloma, acute lymphoblastic leukemia, and diffuse large B-cell lymphoma. As early studies in patients with B-cell chronic lymphocytic leukemia (B-CLL) showed that addition of prednisone to chlorambucil augmented response rate but not median survival, glucocorticoids are not generally a standard component of initial therapy for patients with B-CLL (1, 2). Nonetheless, two studies of high-dose glucocorticoid therapy have suggested that glucocorticoids can be of clinical benefit to a subset of patients with treatment-refractory B-CLL (3, 4). Despite frequent responses to glucocorticoid treatment, monotherapy with glucocorticoids is not curative in any lymphoid malignancy, but the mechanisms underlying clinical glucocorticoid resistance remain controversial. Structural alterations in the glucocorticoid receptor (GR) are commonly identified in lymphoid cell lines that have been selected for glucocorticoid resistance by prolonged culture in dexamethasone, but comparable alterations in primary malignant lymphoid cells have been only infrequently reported (5–9). A detailed analysis of treated B-CLL patients failed to identify abnormalities in either the DNA- or steroid-binding domains of leukemic GRs (10). Nonstructural modifications of glucocorticoid signaling pathways are likely to be important in clinical glucocorticoid resistance, and efforts to identify and reverse these modifications may be therapeutically useful (8, 9). Several clinical studies in patients with acute and chronic lymphoid leukemias have reported a correlation between low leukemic cell GRα expression levels and poor response to treatment (11–13). However, numerous exceptions to such correlative studies have also been reported, leading to the suggestion that clinical resistance to glucocorticoids may also result from unrelated downstream signaling alterations (reviewed in ref. 14).

Cyclic AMP (cAMP)–mediated signaling can favorably alter the apoptotic response to glucocorticoids in specific lymphoid subsets, although the precise molecular explanation for this relationship remains unclear. Seminal early work done by S. Bourgeois et al. showed that isolation of WEHI-7 cells, a murine T-cell lymphoma line, that were resistant to cAMP-mediated apoptosis due to alterations in protein kinase A (PKA) made the subsequent development of spontaneous glucocorticoid-resistant cells occur at higher frequencies (10−2) than in wild-type cells (<10−10; ref. 15). Gruol and Altschmied subsequently determined that RU486, ordinarily a GR antagonist for

Authors’ Affiliations: 1Evans Department of Medicine, Section of Hematology and Oncology, Boston Medical Center, and 2Department of Pathology, Boston University School of Medicine, Boston, Massachusetts

Received 2/2/07; revised 4/30/07; accepted 5/17/07.

Grant support: National Cancer Institute grant CA 106705.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Adam Lerner, Section of Hematology/Oncology, Evans Department of Medicine, Evans Biomedical Research Center 420, 650 Albany Street, Boston, MA 02118. Phone: 617-638-7504; E-mail: lernwara@bu.edu.

© 2007 American Association for Cancer Research.

doi:10.1158/1078-0432.CCR-07-0276

Cancer Therapy: Preclinical

Cancer Therapy: Preclinical
glucocorticoids-induced lymphoid cytology, becomes an agonist in the setting of cotreatment with a cAMP analogue (16). Conversely, McConkey et al. reported that GR-deficient ICR.27 cells, a variant of the CEM T-cell lymphoma line, are insensitive to cAMP-induced apoptosis. Transfection of ICR.27 cells with the GR restored sensitivity to cAMP-mediated apoptosis (17). Finally, the catalytic subunit of PKA has been shown to associate with the GR (18).

One critical factor that regulates lymphoid sensitivity to glucocorticoids is the level of GR expression. Gruol et al. determined that treatment of Wehi-7 cells with cAMP analogues raised GR transcript and protein levels (19). Several mechanisms have been proposed to explain why GR transcript levels increase following treatment of specific cell subsets with agents that augment cAMP signaling. In studies of rat hepatoma cells, Dong et al. (20) reported that treatment with 8-bromo-cAMP increases GR mRNA half-life from 4 to 10 h. Because treatment of such cell cultures with inhibitors of protein or mRNA synthesis had no effect on the ability of 8-bromo-cAMP to increase GR transcript levels, Dong et al. argue that a principal mechanism by which cAMP signaling augments GR transcript levels must be through GR mRNA stabilization. In contrast, using transfection of GR promoter luciferase constructs into HeLa cells, Penuelas et al. (21) determined that treatment with the adenylate cyclase activator forskolin doubled the transcriptional activity of the human GR promoter. After mapping and testing five putative cAMP response element (CRE)-binding sites, the authors showed loss of forskolin inducibility in promoter constructs shorter than 1 kb and the presence of a CRE element that bound CRE in vitro in shift assays. Thus, it seems that in some cell lineages, cAMP-induced augmentation of GR transcript levels is due to augmented transcription rather than mRNA stabilization.

Type 4 cAMP phosphodiesterase (PDE4) inhibitors offer a therapeutically plausible means by which to take advantage of the phenomenon of cAMP-mediated augmentation of glucocorticoid sensitivity in malignant lymphoid cells. The PDE4 family plays a key role in catabolizing cAMP in a variety of human hematopoietic cells, and PDE4 inhibitors are in late-stage clinical studies for a variety of inflammatory illnesses, including asthma and chronic obstructive disease (22). In prior clinical studies for a variety of inflammatory illnesses, including asthma and chronic obstructive disease (22). In prior cell culture and isolation. Blood samples were obtained in heparinized tubes with Institutional Review Board–approved consent from flow cytometry–confirmed B-CLL patients that were either untreated or for whom at least 1 month had elapsed since chemotherapy. Patients with active infections or other serious medical conditions were not included in this study. Patients with WBC counts of <15,000/μL by automated analysis were excluded from this study. Whole blood was layered on Ficoll-Histopaque (Sigma) and peripheral blood mononuclear cells (PBMC) isolated after centrifugation. PBMCs were washed and resuspended at 1 × 10^6 cells/mL in complete media [RPMI 1640 (Mediatech) supplemented with 10% fetal bovine serum (Sigma), 20 mmol/L L-glutamine, 100 IU/mL penicillin, and 100 μg/mL streptomycin (Mediatech)]. PBMCs were found to contain >90% B-CLL by fluorescence-activated cell sorting (FACS) without additional purification. Normal B cells, T cells, and monocytes were obtained from anonymous healthy donors (New York Biologics) and isolated via antibody-coupled magnetic bead–negative depletion per the manufacturer’s protocol (Miltenyi) from PBMC. Polymorphonuclear cells (PMN) were obtained by erythrocyte depletion of whole blood via dextran sedimentation, followed by removal of PMBCs using Ficoll separation. With the exception of PMNs, which were used immediately after purification, all other primary normal and malignant cell populations were rested overnight at 37°C before use.

Western blot analysis. Following cell culture, cells were collected by centrifugation (400 × g; 10 min), washed once with PBS, and lysed in ice-cold 10 mmol/L HEPES-NaOH buffer (pH, 7.4) containing 1% Triton X-100, 10% glycerol, 25 mmol/L β-glyceroephosphate, 100 mmol/L NaCl, 2 mmol/L EDTA, 2 mmol/L EGTA, 1 mmol/L DTT, 1 mmol/L vanadate, 1 mmol/L phenylmethylsulfonyl fluoride, and 1 mmol/L benzamidine. Cell lysates were transferred to 1.5-ml tubes and centrifuged at 14,000 rpm for 30 min (5°C) in a microcentrifuge to clarify samples of insoluble cellular debris. Concentrations of soluble proteins in samples of clarified supernatants were determined using Bradford assays. Samples were heat denatured at 100°C for 5 min in protein-denaturing sample buffer. Levels of GR protein expression were examined in 50-μg aliquots of denatured protein samples that were subjected to electrophoretic separation through 8% SDS-polyacrylamide gels followed by electrotransfer onto Immobilon-P membrane (Millipore) in 10 mmol/L 3-(cyclohexylamino)-1-propanesulfonic acid buffer (pH, 11) containing 10% methanol. Primary GR antibodies (Santa Cruz Biotechnology, sc-1002) and secondary goat anti-rabbit immunoglobulin G (IgG) conjugated to horseradish peroxidase (HRP; Santa Cruz Biotechnology, sc-2004) were diluted at 1:500 and 1:5,000, respectively, in TBS [20 mmol/L Tris-HCl (pH, 7.6); 137 mmol/L NaCl; 0.1% Triton X-100] containing 5% nonfat milk (w/v) to immunoblot proteins on Western blot membranes. Immunocomplexes with HRP activity on membranes were developed using enhanced chemiluminescence reagent (Pierce) as substrate and visualized by exposure to an X-ray film. Membranes were blotted with primary monoclonal anti-α-tubulin (Sigma, T5168) to control for equal loading of protein samples on gels and transfer onto membranes.
Real-time PCR for GR exon 1A3-2, 1B-2, 1C-2, 8-9α, and 8-9β transcripts. Cells were plated at a concentration of 1 × 10⁶ cells/ml in complete media with or without drug treatment as indicated and incubated at 37°C for various times as indicated. Total RNA was obtained using the RiboPure isolation kit (Ambion) per the manufacturer’s protocol. Reverse transcription of 2 to 5 μg of total RNA was carried out with the Superscript III reverse transcription kit (Invitrogen) primed with random hexamers. An assay for the GR exon 8-9α transcript was devised using primer3 software. The forward and reverse primers were 5'-AGCCATTTGCAAGAGGGAGG-3' and 5'-TGATTGGTGATGATTTCAGCTA-3'. The forward and reverse primers for the exon 8-9β splice site was 5'-TGGTGA-GATGTCAGTCAGTTTGA-3' (28). The curves for the amplification of GRα and RNA did not vary by more than 10%. All oligonucleotides were purchased from IDT.

Apoptosis assays. One million cells were incubated in duplicate in 48-well plates with or without drug treatment as indicated for 48 h in 1 mL of complete media. Cells were transferred to polypropylene Falcon FACS tubes and incubated for 10 min at 37°C with Hoechst 33342 (Molecular Probes) at a final concentration of 0.25 μg/mL. Cells were then stored on ice until analysis on a MoFlo cytometer using a 450-nm bandpass filter. In some cases, apoptosis was detected as membrane depolarization with dihydro-oxacarbocyanine (DiOCl(3)) from Molecular Probes at a concentration of 400 nmol/L. DiOCl(3)-stained samples were incubated for 30 min at 37°C and stored on ice until analysis on a FACScan (Becton Dickinson). Results obtained from Hoechst 33342 and DiOCl(3) staining were validated with Annexin V–propidium iodide (PI) staining per the manufacturer’s protocol (BD). FACScan data were analyzed using FlowJo software (Tree Star Inc.) by gating for the apoptotic population. The level of apoptosis detected in B-CLL cultures did not differ by more than 10% when measured by Hoechst 33342 or DiOCl(3).

Statistical analysis. Statistical analysis and plotting were done using Prism version 4 (GraphPad Software) and SPSS version 12 (SPSS Inc.). The significance of the main and interaction effects was determined via repeated-measures ANOVA tests with significance of subsequent pairwise comparisons via Bonferroni post hoc tests. In some cases multivariate ANOVA (MANOVA) were used as indicated when the data violated the sphericity assumption for ANOVA.

Results

Rolipram augments GRα transcript and protein levels in B-CLL cells in a time- and dose-dependent manner. Given prior reports that cAMP analogues augment GR levels in a subset of cell types, we used comparative quantification real-time reverse transcription-PCR (RT-PCR) to determine whether treatment of B-CLL cells with a PDE4 inhibitor altered expression of GRα transcript. In leukemic cells from eight patients, treatment of B-CLL cells with the PDE4 inhibitor rolipram (20 μmol/L) augmented GRα transcript levels in a time- and dose-dependent manner. The effect of rolipram exposure time on GRα transcript levels was found to be significant by ANOVA (P = 0.017). GRα transcript levels rose significantly over the first 6 h to a mean of 4.8 ± 0.2-fold above baseline (P = 0.028) and maintained such a 4-fold increase for at least 24 h (Fig. 1A). Although comparable augmentation of GRα transcript levels was observed at rolipram doses ranging from 1 to 20 μmol/L, significant augmentation was not observed at 0.1 μmol/L rolipram, a concentration at or below the EC50 of rolipram for the

Fig. 1. GRα expression is up-regulated in B-CLL cells following treatment with the PDE4 inhibitor rolipram. A, B-CLL cells were treated for the indicated lengths of time with rolipram (20 μmol/L), followed by RNA isolation, cDNA synthesis, and real-time PCR for GRα using oligonucleotides that spanned exons 8 and 9α. Each point represents the fold increase in transcript levels of an individual patient sample relative to the same patient’s CLL cells treated with vehicle (DMSO) alone. The mean fold increase in transcript level is denoted with a horizontal line. *, significant main effect for time at P < 0.05 (ANOVA). B, B-CLL cells from an individual patient were treated for 4 h with transcript levels of an individual patient sample relative to the same patient’s CLL cells treated with vehicle (DMSO) control. The data are representative of one of two similar experiments. C, B-CLL cells were treated with DMSO alone (0 time point) or rolipram (20 μmol/L) for the indicated amount of time, followed by lysis, protein quantification, and immunoblot analysis for GRα protein expression (GRα). α-Tubulin was also assessed by immunoblot analysis as an internal loading control. Results from two patients are shown and are representative of four patients tested.

3 Available at http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi.
inhibition of tumor necrosis factor secretion (Fig. 1B; ref. 29). Addition of the adenylate cyclase stimulator forskolin did not significantly augment GRα transcript in B-CLL cells, either when used alone or in combination with rolipram, a finding in keeping with prior studies demonstrating that rolipram activates PKA in B-CLL in the absence of exogenous adenylate cyclase activation (data not shown). Western blot analysis of rolipram-treated B-CLL cells from four patients showed that PDE4-inhibitor–induced GR transcript up-regulation was associated with an increase in GR protein at 4 to 6 h (Fig. 1C).

cAMP-mediated augmentation of GR transcript levels has been variably attributed to increased GR half-life (in rat hepatoma cells) or GR transcription (in HeLa cells; refs. 20, 21). To establish whether the increased levels of GR transcript observed in rolipram-treated B-CLL cells were the result of altered transcript half-life, we treated B-CLL cells with vehicle alone (DMSO) or rolipram (20 μmol/L) for 4 h, followed by treatment with the RNA polymerase inhibitor actinomycin D (10 μg/mL) for varying periods of time. Assessment of GRα transcript levels following such actinomycin D treatment revealed that the half-life of GRα transcript was not altered by rolipram treatment (P = 0.88; Fig. 2), suggesting that in B-CLL cells, cAMP-mediated augmentation of GRα transcript occurs by a transcriptional mechanism.

Rolipram-mediated GRα transcript up-regulation is not observed in a range of normal hematopoietic cell types. To establish the specificity of PDE4 inhibitor-mediated GR transcript up-regulation, we carried out real-time RT-PCR analyses in a range of normal hematopoietic cells. Rolipram treatment did not augment GRα transcript levels in unpurified human mononuclear cells or in purified populations of human T cells, B cells, neutrophils, and monocytes (Fig. 3). In the absence of basal adenylate cyclase activity, PDE4 inhibitors may be relatively ineffective in activating cAMP-mediated signal transduction. However, forskolin (40 μmol/L), either alone or in combination with rolipram, did not induce GR transcript up-regulation in these normal hematopoietic cell populations (data not shown). Because it is possible that a PDE family other than PDE4 might regulate GR levels in these cell populations, we examined whether the addition of IBMX (50 μg/mL), a competitive inhibitor of 9 of the 11 currently known PDE families, led to an increase in GR transcript. No augmentation of GR transcript levels was observed in unpurified human mononuclear cells (a predominantly T-cell preparation) or in purified populations of human monocytes (data not shown).

To establish whether the observed effect of PDE4 inhibitors on B-CLL GRα transcript levels was simply a function of lymphoid transformation, we examined primary leukemic cells from a patient with T-CLL and a patient with Sezary syndrome. In neither case was rolipram-induced augmentation of GRα transcript levels observed (Fig. 3).

Roflumilast and cilomilast augment glucocorticoid-mediated apoptosis and GRα transcript levels. To determine whether the alterations in GRα transcript observed following rolipram treatment of B-CLL cells are shared by other structurally distinct PDE4 inhibitors, we examined cilomilast and roflumilast, two PDE4 inhibitors that have been used in clinical trials testing the activity of PDE4 inhibitors in asthma and chronic obstructive pulmonary disease (Fig. 4A; refs. 30, 31). Consistent with the hypothesis that PDE4 is in fact the rolipram target that results in augmented GRα transcript levels, cilomilast and roflumilast increased GRα transcript levels (P = 0.012; ANOVA) in B-CLL cells (Fig. 4B). As previously observed with rolipram, both cilomilast (50 μmol/L) and roflumilast (1.0 μmol/L) augmented the efficacy with which glucocorticoids induce apoptosis in B-CLL (Fig. 4C). In pooled data from 10 B-CLL patients, combining PDE4 inhibitor and glucocorticoid treatment significantly augmented apoptosis relative to either agent alone (P < 0.01; MANOVA). Despite this statistically significant effect, however, it is important to point out that among these 10 leukemic cell samples, several did not in fact show PDE4 inhibitor–mediated augmentation of glucocorticoid apoptosis. Such heterogeneity is similar to results we previously obtained in studies with rolipram. One patient whose leukemic cells were very sensitive to glucocorticoid-mediated apoptosis showed no further augmentation with the addition of cilomilast or roflumilast. Another leukemic cell sample that had relatively high basal apoptosis (39%) showed little or no sensitivity to any of the drug treatments. It is possible that this
heterogeneity in apoptotic responses to combined glucocorticoid/PDE4 inhibitor treatment is due to genetic heterogeneity of the leukemias in this patient population.

The synergistic apoptotic effects of combined PDE4 inhibitor/glucocorticoid treatment can be observed following drug treatment for as little as 2 h. If the potential therapeutic benefit of combined PDE4 inhibitor/glucocorticoid therapy is to be explored clinically, it will be important to determine the length of time leukemic cells must be exposed to both agents to augment glucocorticoid-mediated apoptosis. CLL cells were treated with vehicle alone, rolipram (20 μmol/L), dexamethasone (1 μmol/L), or the combination of rolipram and dexamethasone for varying periods of time, followed by washing and completion of cell culture for 48 h. Combined rolipram/glucocorticoid treatment for as little as 2 h augmented apoptosis relative to treatment with either drug alone (Fig. 4D). Treatment for 8 h with the drug combination resulted in a level of apoptosis that approached that observed following a full 48 h of combined drug treatment. Although our studies did not address how much of the compounds remain associated with the leukemic cells after washing, these results suggest that PDE4 inhibitors potentiate glucocorticoid-mediated apoptosis in a relatively short period of time.

PDE4 inhibitors vary the augment different classes of GRα transcript. Transcription of the GR gene is regulated by three promoters, 1A, 1B, and 1C (32). Prior studies in the human B-cell line IM-9 have shown that under basal conditions, roughly 1%, 23%, and 76% of GRα transcripts are derived from promoters 1A, 1B, and 1C, respectively (28). Using previously validated real-time PCR assays that detect splicing of exons 1A3, 1B, and 1C to exon 2, we examined leukemic cells from six B-CLL patients for the effect of rolipram treatment on levels of GRα transcripts derived from these three promoters. As illustrated in Fig. 5A, rolipram (20 μmol/L) augmented GR transcripts derived from each of the three promoters: exon 1A3 (22.2 ± 7.4-fold), exon 1B (3.6 ± 0.5-fold), and exon 1C (7.1 ± 0.9-fold). The up-regulation observed for transcripts containing exon 1A3 was significantly higher than that observed for transcripts containing exon 1B (3.6 ± 0.5-fold; P < 0.05; ANOVA).

GRβ has been reported to suppress transactivation of GRα by synthetic glucocorticoids, and high levels of GRβ may correlate with insensitivity to glucocorticoid-induced apoptosis (33, 34). We therefore examined GRβ regulation by PDE4 inhibitors in B-CLL. Treatment with rolipram augmented GRβ transcript levels 7-fold relative to levels observed in untreated CLL cells (Fig. 5). Basal levels of GRβ in B-CLL cells seem to be far lower than those of GRα because the real-time PCR threshold cycle numbers we observed for GRβ were 10 cycles greater than those for GRα despite comparable efficiency of amplification. These results are similar to the 1,000-fold lower GRβ level reported by Vedeckis et al. (28) using the same oligonucleotide primers in

![Fig. 4](https://example.com/fig4.png)

**Fig. 4.** Effect of several structurally distinct PDE4 inhibitors on glucocorticoid-mediated apoptosis and GRα transcript levels. A, molecular structures of rolipram, roflumilast, and cilomilast. B, B-CLL cells were treated as indicated with vehicle control (DMSO), 50 μmol/L cilomilast, 1.0 μmol/L roflumilast or 20 μmol/L rolipram for 4 h followed by RNA isolation and RT-PCR analysis for GRα transcript. The mean fold increase in transcript level of five patients is denoted with a horizontal line. C, B-CLL cells were treated for 48 h with PDE4 inhibitors alone or in the presence of increasing dosages of dexamethasone, as indicated, followed by assessment for apoptosis by FACS analysis. The PDE4 inhibitors cilomilast, roflumilast, and rolipram were added at 50, 1.0, and 20 μmol/L, respectively. Columns, mean of 10 patients tested; bars, SE. D, B-CLL cells were treated for 0, 4, 8, 24, or 48 h with vehicle alone, rolipram (20 μmol/L), dexamethasone (1 μmol/L), or the combination of rolipram and dexamethasone. The drugs were removed by washing at the indicated time, followed by completion of culture in media alone until 48 h had elapsed.
a quantitative real-time RT-PCR study of basal and glucocorticoid-treated GRα and GRβ transcript levels in the EBV-transformed B-cell line IM-9.

PDE4 inhibitors abrogate the ability of dexamethasone to reduce B-CLL GRα transcript levels. Exposure to glucocorticoids regulates intracellular GR levels, with resultant down-regulation of GR in most cell lineages, including B cells and B lineage cell lines, but with up-regulation of GR in thymocytes and T-ALL–derived cell lines (28). Using a tetracycline-regulated GR promoter transfected into a cell line lacking functional GR, the glucocorticoid-induced autoinduction of GR expression in human T-cell lines has been linked to their increased sensitivity to glucocorticoid-mediated apoptosis (35). We therefore sought to determine whether in CLL cells, cotreatment with PDE4 inhibitors would abrogate glucocorticoid-mediated attenuation of GR transcript levels. As expected, dexamethasone reduced GR transcript levels in CLL cells in a dose-dependent manner such that following treatment for 6 h with 1 μmol/L dexamethasone, GR transcript levels were one-third of those observed in untreated cells (Fig. 5B). In contrast, cotreatment of CLL cells for 6 h with 20 μmol/L rolipram and varying doses of dexamethasone resulted in GR transcript levels above basal levels, even at 1 μmol/L dexamethasone (Fig. 5B). These results suggest that PDE4 inhibitors may augment glucocorticoid-mediated apoptosis in B-CLL cells as a result of their ability to block the normal down-regulation of GR transcript levels in glucocorticoid-treated cells.

Given our prior demonstration that inhibition of PKA signaling with the enantiomeric cAMP antagonist Rp-8-Br-cAMPS substantially or entirely blocked the ability of glucocorticoids to induce apoptosis in B-CLL cells as well as reduced transactivation of GRE–containing reporter constructs, we sought to determine whether the same antagonist blocks PDE4 inhibitor–induced augmentation of GRα transcript levels (26). Pretreatment of CLL cells with Rp-8Br-cAMPS (500 μmol/L) markedly reduced rolipram-induced augmentation of GRα transcript levels at 4 h (Fig. 5C). These results are consistent with the hypothesis that PDE4 inhibitors regulate GRα transcript levels by a cAMP- and PKA-mediated mechanism.

Discussion

This study shows that treatment with several structurally distinct PDE4 inhibitors augments GR transcript levels in B-CLL cells but not in normal circulating hematopoietic cells. Because cotreatment with PDE4 inhibitors and glucocorticoids also
induces apoptosis in B-CLL cells to levels higher than that observed with either agent alone, these results suggest that the simultaneous use of these two classes of drug might be relatively selectively toxic to CLL cells (26). Although it is experimentally difficult to determine whether the alterations in GR expression account for the augmented apoptosis observed when these drugs are combined, a variety of prior studies have shown that levels of GR can play an important role in determining the outcome of glucocorticoid treatment. In cell lines expressing different levels of GR, the magnitude of transcriptional responses to glucocorticoids are roughly proportional to the number of receptors per cell (36). Thymocytes from transgenic mice carrying two extra copies of the GR show enhanced sensitivity to glucocorticoid-mediated apoptosis (37).

Consistent with actinomycin D experiments demonstrating that PDE4 inhibitors do not substantially alter GR transcript half-life, we find that rolipram augments GR transcripts derived from different promoters to varying degrees in CLL cells, suggesting a transcriptional mechanism for the observed increase in GR transcript levels. GR transcription in human lymphoid cells is regulated by at least three promoters (A-C), although the open reading frame of the GR gene, which begins in exon 2, is not altered by promoter usage (32). A quantitative analysis in the IM-9 human B cell line revealed that in such cells, promoters 1A, 1B, and 1C accounted for 1%, 23%, and 76% of all GRα transcripts, respectively (28). Alternative splicing of transcripts derived from the most 5’ promoter, 1A, results in three types of transcripts: 1A1, 1A2, and 1A3, the last of which was the most abundant (32). Although a prior study in HeLa cells has suggested cAMP-mediated regulation of the most 3’ promoter, 1C, the effects of cAMP signaling on GR promoters 1A and 1B have not been reported (21). Transcripts containing 1B and 1C seem to be relatively ubiquitously expressed, whereas expression of exon 1A-containing transcripts is particularly high in cell lines of hematopoietic lineage (32). In B-CLL cells, treatment with PDE4 inhibitors augments 1A3 transcripts to a greater degree than other GR transcripts (1A3 > 1B; P < 0.05). It is of interest that basal levels of GR transcripts containing exon 1A correlate with sensitivity to glucocorticoid-induced apoptosis because expression of this form of GR transcript is particularly high in thymocytes and T lymphoblastoid cell lines (38). Although the functional significance of the fact that PDE4 inhibitors preferentially induce expression of exon 1A3-containing GR transcripts in B-CLL cells remains unknown, it is possible that varying 5’ untranslated regions could alter either GR mRNA translation start site or translation efficiency. Two alternative translation initiation sites in exon 2 give rise to the A and B forms of the GR. GRα B has twice the biological activity of GRα A in gene expression studies, and different tissue types have differing ratios of GRα A and GRα B (39, 40).

Among all the primary hematopoietic cell populations tested, augmentation of GR transcript levels by PDE4 inhibitors is unique to B-CLL cells. This finding is in keeping with a prior study in which, among a variety of circulating hematopoietic cells examined, PDE4 inhibitor–induced EPAC activation was found only in B-CLL cells (25). The explanation for the unique impact of PDE4 inhibitor treatment on signaling in B-CLL cells remains unknown. Although we do not observe rolipram-induced up-regulation of GR transcript in primary circulating B-cell samples, it is still possible that comparable responses might be observed in a normal B-cell population that is not well represented among circulating B cells. Because PDE4 inhibitors have potent effects on a variety of primary circulating hematopoietic cells, particularly T cells and monocytes, it is clearly not the case that the selective augmentation of GR transcript observed in B-CLL cells is due to the fact that PDE4 inhibitors initiate cAMP-mediated signaling only in B-CLL cells. Instead, the selectivity of the effects observed in CLL cells may be due to the magnitude or kinetics of the cAMP response, the effector proteins activated (i.e., type 1 versus type 2 PKA, EPAC) or, perhaps most likely, cell type–specific signaling induced by cAMP effector protein activation in B-CLL cells.

Glucocorticoids regulate expression of GR. In lymphoid cell subsets that are particularly sensitive to glucocorticoid-mediated apoptosis, glucocorticoids augment GR transcript levels (41). In other cell lineages, including B lineage cells, glucocorticoids reduce GRα transcript levels (28). Consistent with this literature, we find that treatment of B-CLL cells with dexamethasone reduces GRα transcript levels in a dose-dependent manner. In contrast, treatment with the combination of dexamethasone and a PDE4 inhibitor augmented GRα transcript levels. Although treatment with both drugs resulted in the augmentation of GRα transcript intermediate between those observed with treatment with either drug alone, even at the highest dose of dexamethasone used (1 μmol/L), cotreatment resulted in an increment rather than a decrement in GRα transcript levels. These results suggest that PDE4 inhibitors may increase glucocorticoid-mediated apoptosis in B-CLL cells because they counteract the normal dampening of glucocorticoid-mediated signaling that occurs in B lineage cells as a result of glucocorticoid-induced down-regulation of GRα levels.

High-dose glucocorticoid therapy can lead to clinical responses in a subset of patients with treatment refractory B-CLL (3, 4). The experiments described in this study suggest that the addition of a PDE4 inhibitor to such therapy might fairly selectively augment apoptosis in B-CLL cells as a result of augmentation of GR transcript levels. Our observation that treatment with PDE4 inhibitors for as few as 4 h augments glucocorticoid-induced killing of B-CLL cells augers well for the potential clinical applicability of PDE4 inhibitor/glucocorticoid therapy for B cell malignancies because it is likely that therapeutically effective serum levels of PDE4 inhibitors could be safely maintained for such a period of time. Our future studies will focus on the mechanisms underlying the selectivity with which PDE4 inhibitors alter cAMP metabolism in CLL cells.

Acknowledgments

We thank Lewis Weintraub, M.D., for assistance in obtaining leukemic cell samples.

References

4. Thornton PD, Hamblin M, Teleaven JG, Matutes E,

Cancer Therapy: Preclinical


Phosphodiesterase 4 Inhibitors Augment Levels of Glucocorticoid Receptor in B Cell Chronic Lymphocytic Leukemia but Not in Normal Circulating Hematopoietic Cells


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/13/16/4920

Cited articles
This article cites 41 articles, 17 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/13/16/4920.full#ref-list-1

Citing articles
This article has been cited by 4 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/13/16/4920.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.